Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px
Document › Details

Bone Therapeutics S.A.. (1/12/16). "Press Release: Bone Therapeutics to Participate in Key Investor and Partnering Conferences in the First Half of 2016". Gosselies.

Organisations Organisation Bone Therapeutics S.A. (Euronext Brussels + Paris: BOTHE)
  Group Bone Therapeutics (Group)
  Organisation 2 KBC Securities N.V.
  Group KBC Group (Group) [since 3/05]
Products Product BIO-Europe Spring 2016 Stockholm
  Product 2 Knowledge for Growth 2016 Ghent (FlandersBio)
Index terms Index term Bone Therapeutics–Life Sciences Partners: investor conference, 201603 supply service Bone Therapeutics participates at BioCapital Europe
  Index term 2 Bone Therapeutics–Van Lanschot: investor conference, 201604 supply service Bone Therapeutics at Kempen Healthcare/Life Sciences Conference
     


BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces that it will participate in several key investor and partnering conferences in the first half of 2016.


Institutional investor conferences:

Degroof Petercam Healthcare CEO Seminar
Date: 3 February
Venue: Brussels, Belgium

BioCapital Europe
Date: 9 March
Venue: Amsterdam, The Netherlands

KBC Securities Healthcare Conference
Date: 22 March
Venue: Brussels, Belgium

Kempen & Co Healthcare/Life Sciences Conference
Date: 7 April
Venue: Amsterdam, The Netherlands


Partnering conferences:

BIO-Europe Spring
Date: 4-6 April
Venue: Stockholm, Sweden

Knowledge for Growth
Date: 26 May
Venue: Ghent, Belgium

BIO International Convention
Date: 6-9 June
Venue: San Francisco, US


Bone Therapeutics will also be present at the following retail event:

VFB Happening
Date: 16 April
Venue: Antwerp, Belgium


For further information, please contact:

Bone Therapeutics SA
Enrico Bastianelli, Chief Executive Officer
Wim Goemaere, Chief Financial Officer
Tel: +32 (0)2 529 59 90
investorrelations@bonetherapeutics.com

For Belgium and International Media Enquiries
Consilium Strategic Communications
Amber Fennell, Jessica Hodgson,
Lindsey Neville and Hendrik Thys
Tel: +44 (0) 20 3709 5701
bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries
NewCap Investor Relations & Financial Communications
Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau
Tel: + 33 (0)1 44 71 94 94
bone@newcap.fr


About Bone Therapeutics

Bone Therapeutics is a leading biotechnology company specializing in the development of cell therapy products intended for bone fracture repair and fracture prevention. The current standard-of-care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative regenerative products containing osteoblastic/bone-forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.

PREOB®, Bone Therapeutics’ autologous bone cell product, is currently in pivotal Phase IIB/III clinical studies for two indications: osteonecrosis and non-union fractures, and in Phase II for severe osteoporosis. ALLOB®, its allogeneic “off-the-shelf” bone cell product, is in Phase II for the treatment of delayed-union fractures and spinal fusion procedures. The Company also runs preclinical research programs and develops novel product candidates.
Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics’ regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 11 patent families. Further information is available at www.bonetherapeutics.com.


Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

   
Record changed: 2017-07-02

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px

More documents for Bone Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px download




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px